key: cord-0790109-w4pxrvyk
authors: Westblade, Lars F.; Simon, Matthew S.; Satlin, Michael J.
title: Bacterial Co-Infections in Coronavirus Disease 2019
date: 2021-04-08
journal: Trends Microbiol
DOI: 10.1016/j.tim.2021.03.018
sha: ec618ed3460cb57ef605ffea4ebaadd98a071f45
doc_id: 790109
cord_uid: w4pxrvyk

Bacterial co-infections increase the severity of respiratory viral infections and were frequent causes of mortality in influenza pandemics, but have not been well characterized in patients with coronavirus disease 2019 (COVID-19). The aim of this review was to identify the frequency and microbial etiologies of bacterial co-infections that are present upon admission to the hospital and that occur during hospitalization for COVID-19. We found that bacterial co-infections were present in <4% of patients upon admission and the yield of routine diagnostic tests for pneumonia was low. When bacterial co-infections did occur, Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae were the most common pathogens and atypical bacteria were rare. Although uncommon upon admission, bacterial infections frequently occurred in patients with prolonged hospitalization and Pseudomonas aeruginosa, Klebsiella spp., and S. aureus were common pathogens. Antibacterial therapy and diagnostic testing for bacterial infections are unnecessary upon admission in most patients hospitalized with COVID-19, but clinicians should be vigilant for nosocomial bacterial infections.

procalcitonin level >0.5 ng/mL was only 9.3% [13] . On the other hand, the negative predictive value of a white blood cell count <8.8x10 9 cells/µL, absolute neutrophil count <6.8x10 9 cells/µL, and procalcitonin level ≤0.5 ng/mL are ≥98%.

While bacterial co-infections are overall rare among patients who are hospitalized for COVID-19, they are more common among patients admitted to an ICU, occurring in 6-29% of these patients [13, 22, [24] [25] [26] [27] [28] . Although some of the increased frequency of bacterial co-infections in patients admitted to an ICU may be related to increasing use of blood and respiratory tract cultures to diagnose bacterial infections [17] , these patients may also be more likely to have positive cultures [13, 29, 30] .

Clinicians face a difficult challenge in deciding which hospitalized patients with COVID-19 to treat with antibacterial therapy. Figure 1 illustrates a recommended approach for diagnosing bacterial co-infection and antibiotic management upon hospital admission in patients with COVID-19. We recommend pursing microbiologic diagnostic tests and initiating empirical antibiotic therapy only in patients who are critically ill, severely immunocompromised, or have radiographic or laboratory findings suggestive of bacterial co-infection. When empirical therapy is warranted, we recommend ß-lactam agents and provide guidance for when coverage of Pseudomonas aeruginosa, atypical bacteria, and/or MRSA is warranted.

(PPE) required for SARS-CoV-2. Hospitals in New York City (NYC) noted a surge in blood culture utilization during the peak of the pandemic, with 35% more cultures analyzed than the same time during the previous year, that at times overwhelmed the capacity of blood culture instruments [31] . Moreover, the rate of positive blood cultures in patients with COVID-19 has been shown to be significantly lower than in patients without COVID-19 [32] . As with the initiation of empirical antibacterial therapy, blood cultures should not be routinely ordered in hospitalized patients with COVID-19. Instead, they should be selectively ordered in patients with a suspicion for bacterial co-infection, which would include patients for whom empirical antibacterial therapy is being initiated.

Most patients who present to the hospital with COVID-19 do not have a productive cough and thus are not able to produce sputum for culture [13, 33] . Studies report that respiratory tract cultures yielded a pathogen in 3-19% of the general population of hospitalized patients with COVID-19 and in 10-21% of patients admitted to ICUs (Table 2) [13, 14, 18, 19, 26, 29, 30 ].

Based on these data, we recommend the use of respiratory tract cultures only in the minority of patients who have a productive cough and for whom empirical antibacterial therapy is being considered or in patients who are admitted to the ICU and intubated for respiratory failure.

Only 11 (0.9%) out of 1237 patients had a positive urine pneumococcal antigen test result (Table 2) [14, 16, 17-19, 26, 27, 30] . Thus, we do not recommend routine use of urine pneumococcal antigens in patients hospitalized with COVID-19. However, this test may be considered in patients with severe disease for whom antibacterial therapy is being considered, which is in line with guidelines of the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) for community-acquired pneumonia (CAP) [34] . The yield of urine legionella antigen tests is even lower, with only one (0.08%) positive test in 1263 patients (Table   2 ) [14, 16, 17-19, 26, 27, 30] . None of the samples that were sent for Mycoplasma pneumoniae J o u r n a l P r e -p r o o f Journal Pre-proof and Chlamydia pneumoniae PCR were positive (Table 2) [18, 27, 29, [35] [36] [37] . Thus, we do not recommend the routine use of urine legionella antigens or atypical pneumonia PCR panels in patients with COVID-19.

The most common bacterial respiratory and bloodstream pathogens that caused co-infection upon admission with COVID-19 are outlined in Figure 2 . Of 132 total bacterial respiratory and bloodstream pathogens, the most common were S. aureus (n=41, 31%), S. pneumoniae (n=31, 23%), and H. influenzae (n=15, 11%). Thus, for patients hospitalized with COVID-19 for whom empirical antibacterial therapy is indicated, coverage of these organisms is recommended ( Figure 1 : empirical antibiotic regimens).

Initial treatment strategies for CAP, as recommended by the ATS and IDSA, consist of combination therapy with a ß-lactam and a macrolide or a respiratory fluoroquinolone [34] .

These regimens will generally cover S. aureus, S. pneumoniae, and H. influenzae, with the exception of MRSA. The choice of whether to include anti-MRSA therapy in the empirical treatment of bacterial co-infection should be influenced by the local geographic prevalence of MRSA and/or prior isolation of MRSA from the patient ( Figure 1) . Furthermore, collecting a nares swab for MRSA PCR can guide the use of anti-MRSA therapies. This test has high specificity for MRSA pneumonia and a high negative predictive value for ruling out MRSA in patients with and without COVID-19 [38, 39] . Thus, a reasonable strategy to pursue in critically ill patients admitted with COVID-19 pneumonia to an ICU is to begin anti-MRSA coverage, collect a nares swab for MRSA PCR, and discontinue anti-MRSA coverage if the PCR is negative.

Pseudomonas aeruginosa was identified as a bacterial respiratory pathogen in 10 (8%) of the 132 co-infections outlined above. Thus, routine empirical coverage of P. aeruginosa is generally unnecessary, unless the patient has had a history of infection due to this organism, a chronic lung disease associated with P. aeruginosa pneumonia, such as bronchiectasis [40] , or recent parenteral antibiotic exposure ( Legionella pneumophila may be more common in critically ill patients requiring ICU admission.

Although only a single urine legionella antigen test was positive, L. pneumophila was identified by culture or PCR in three of 50 bacterial co-infections in studies that only evaluated patients who were admitted to an ICU [24-28].

Although guidelines prefer combination therapy with ß-lactam/macrolide antibiotics to monotherapy with just ß-lactam antibiotics for CAP in hospitalized patients [34] , a recent randomized trial found that the latter is non-inferior when compared to the former in patients with CAP who are admitted to non-ICU wards [42] . Another randomized trial of ßlactam/macrolide combination therapy vs. ß-lactam monotherapy for CAP also found similar J o u r n a l P r e -p r o o f Journal Pre-proof outcomes between groups, except in patients who were infected with atypical pathogens or who were critically ill [43] . A potential benefit of including macrolides in the treatment of CAP is that they may have beneficial immunomodulatory properties [44] . However, randomized trials have not identified a clinical benefit for the use of macrolides in hospitalized patients with COVID-19 [46, 47] . Based on available data, we do not recommend adding macrolides to ß-lactam agents for patients being treated empirically for bacterial co-infection with COVID-19, with the exception of critically ill patients where L. pneumophila co-infection has been observed ( Figure 1 ).

Most studies of bacterial co-infections in patients with COVID-19 did not have a sufficient number of patients to identify differences in outcomes between patients with and without bacterial co-infection. The largest study of bacterial co-infections on admission in our review, however, found that patients with bacterial co-infection had a longer length of hospital stay (median 7 days v. 5 days; P=0.003) and increased in-hospital mortality (48% vs. 18%; P<0.001) compared to patients without bacterial co-infection [13] . However, other smaller studies have not found the same association possibly due to insufficient power or non-respiratory sources of infection [14, 15] .

Frequency and risk factors for hospital-acquired bacterial infections: Table 3 outlines results from nine studies where the primary objective was to assess hospital- 

Three of the four studies that compared outcomes of patients with and without hospital-acquired bacterial infections found an increased mortality rate in the former group [15, 47, 49, 51] .

Garcia-Vidal et al. found that patients with hospital-acquired bacterial infections had a longer length of hospital stay (20 days vs. 9 days, P<0.001) [15] . Bhatt and colleagues found that 53.1% of patients with a secondary BSI died during the hospitalization, compared to 32.8% of controls (P=0.0001) [54] . These findings are similar to those observed in patients hospitalized with influenza, where in one study in-hospital mortality was 45.7% in patients who developed a hospital-acquired bacterial or fungal infection and 11.8% in patients who did not develop a hospital-acquired infection [55] . Vaughn et al. [13] Michigan, USA (38 hospitals) 1 The denominator for this proportion includes 37 patients with bacterial co-infection and 100 randomly selected patients without bacterial co-infection. 2 Of the 35% of patients who received empirical antibiotics, 37% received them for more than 1 week.

J o u r n a l P r e -p r o o f 

Pandemic COVID-19 Joins History's Pandemic Legion

Middle East respiratory syndrome

Bacterial pneumonia and pandemic influenza planning

Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness

Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A (H1N1) virus

Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States

Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections

Critically ill patients with the Middle East Respiratory Syndrome: A multicenter retrospective cohort study

Clinical characteristics of coronavirus disease 2019 in China

Co-infections in people with COVID-19: a systematic review and meta-analysis

Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with COVID-19: A multi-hospital cohort study

An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting

Community acquired co-infection in COVID-19: A retrospective observational experience

Low rate of bacterial co-infection in patients with COVID-19

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series

Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America

Rates of co-infection between SARS-CoV-2 and other respiratory pathogens

Coinfections with SARS-CoV-2 and other respiratory pathogens

Decreased prevalence rate of respiratory pathogens in hospitalized patients during the COVID-19 pandemic: possible role for public health containment measures?

The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: A diagnostic meta-analysis with antimicrobial stewardship implications

Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in respiratory cultures and diagnostic performance of the MRSA nasal polymerase chain reaction (PCR) in patients hospitalized with coronavirus disease 2019 (COVID-19) pneumonia

Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalized

) ß-lactam monotherapy vs. ß-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in

COALITION II): a randomised clinical trial

Hydroxychloroquine with or without azithromycin in mild-tomoderate Covid-19

Predictors and outcomes of HAIs in COVID-19 patients

Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors

Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study

Analysis of the risk factors for nosocomial bacterial infection in patients with COVID-19 in a tertiary care hospital

Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome

Risk factors and outcomes of hospitalized patients with severe COVID-19 and secondary bloodstream infections: A multicenter, case-control study

Risk factors for nosocomial infection among hospitalized patients with severe influenza A(H1N1)pdm09 patients

Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital

Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales infections in New York City COVID-19 patients

Increase in hospital-acquired carbapenem-resistant Acinetobacter baumannii infection and colonization in an acute care hospital during a surge in COVID-19 admissions -New Jersey

Klebsiella pneumoniae infections in COVID-19 patients: a 2-month retrospective analysis in an Italian hospital

Antimicrobial stewardship program, COVID-19, and infection control: Spread of carbapenem-resistant Klebsiella pneumoniae colonization in ICU COVID-19 patients. What did not work?

Impact of severe acute respiratory syndrome coronavirus

Respiratory tract cultures: The yield of respiratory tract cultures is higher than the yield of blood cultures in patients presenting to the hospital with COVID; however, respiratory tract cultures are frequently not obtained because many patients do not have a productive cough

3.5% 57% (median: 3 days)Wang et al. [14] London, England (2 hospitals J o u r n a l P r e -p r o o f